Problems With Biomarkers: A Tale of Three Drugs

Enthusiasm for biomarkers to guide drug development and clinical decision making is high, but given how little we know about them, biomarkers are a risky investment, as shown by experiences with EGFR inhibitors.

By Wendy Diller

Nearly two years ago, the FDA approved AstraZeneca PLC 's gefitinib (Iressa) and a year later ImClone Systems Inc....

More from Global Vision

More from In Vivo